Karl Bergman3.jpg

Karl Bergman

Chief Executive Officer
+46 73 262 53 33

Karl is the CEO at Elypta. He previously led digitalization efforts as Chief Digital Officer at Praktikertjänst, Sweden’s largest private healthcare provider. Before that, he was a Principal in Arthur D. Little’s healthcare & life science practice where he spent eight years assisting clients with strategic challenges across pharma, diagnostics and medtech. Karl holds M.Sc. degrees in Bioengineering as well as in Innovation & Entrepreneurship from Chalmers University of Technology and an MBA from University of Cambridge.

Francesco_Gatto bw.jpg

Francesco Gatto

Chief Scientific Officer

Francesco is a co-founder and the Chief Scientific Officer at Elypta. He was named MIT Innovators Under 35 in Europe in 2018 and Pioneer of the Year for the same list. He holds a Ph.D. in Systems Biology from Chalmers University of Technology and a M.Sc. in Chemical Engineering from the University of Padova. He has spent 5 years modeling cancer metabolism, using genome-scale metabolic networks and -omics data mining at Chalmers as well as a Visiting Scholar at University of California, San Diego. Francesco co-authored 16 scientific papers and submitted 3 patent applications as inventor. His research led him to the invention of Elypta’s diagnostic method.


Board of Directors


Anders Ekblom

Anders is the chairman of the board at Elypta. He has extensive experience as an executive in the biopharmaceutical industry and is currently Chairman or Non-executive board member of several public and private biotech companies. Anders is also Chairman of the Board at Karolinska University Hospital and Board member of the Swedish Research Council. During two decades at AstraZeneca, he was a member of global executive teams including Executive VP Global Medicines Development, Global Head Clinical Development, Global Therapy Area Head, Global Head Science & Technology Integration, and CEO AstraZeneca AB Sweden. Anders is also a board certified MD (Anaesthesiology and Intensive Care), PhD, DDS, and Associate Professor at Karolinska Institute, Stockholm, Sweden and a fellow of the Royal Swedish Academy of Engineering Sciences.

Pontus Ottosson.png

Jens Nielsen

Jens is a co-founder and member of the board at Elypta. He is a Full Professor in Systems Biology at the Chalmers University of Technology and leads a group of more than 60 researchers. He has a very strong international profile in his field. Jens was elected to the National Academy of Engineering and is the recipient of several international awards. His research is focused on systems biology, modeling of metabolism, and metabolic engineering of cell factories, which resulted in more than 600 publications with more than 42,000 citations and over 50 patent applications. He has founded several biotech companies that have raised in total more than €25m in venture capital.


Pontus Ottosson

Pontus is a board member at Elypta and currently serves as Head of Investments at Chalmers Ventures. He previously led P.U.L.S, one of the most successful life science incubator / venture capital firms in Scandinavia, completing exits at a deal value of 1.1 billion SEK. Pontus holds M.Sc. degrees in Mechatronics and Entrepreneurship from Chalmers University of Technology.


Jamal El-Mosleh

Jamal is a board member at Elypta. He is the CEO of the publicly traded pharmaceutical company Annexin and was previously CEO of immuno-oncology company Immunicum (2007-16). Jamal led Immunicum from concept stage to IPO, with multiple successful rounds of financing and initiation of three clinical trials, including in renal cell carcinoma. Jamal holds M.Sc. degrees in Industrial Engineering and Management and Innovation and Entrepreneurship from Chalmers University of Technology.